A share price of Ionis Pharmaceuticals Inc [IONS] is currently trading at $43.59, up 9.14%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IONS shares have gain 8.98% over the last week, with a monthly amount glided 27.79%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ionis Pharmaceuticals Inc [NASDAQ: IONS] stock has seen the most recent analyst activity on July 01, 2025, when Barclays upgraded its rating to a Overweight but kept the price target unchanged to $57 for it. Previously, H.C. Wainwright started tracking the stock with Buy rating on April 07, 2025, and set its price target to $45. On March 31, 2025, Redburn Atlantic initiated with a Neutral rating and assigned a price target of $39 on the stock. BMO Capital Markets downgraded its rating to a Market Perform and decreased its price target to $60 on August 02, 2024. Leerink Partners upgraded its rating to a Outperform and raised its price target to $62 on July 24, 2024. In a note dated June 14, 2024, Bernstein upgraded an Mkt Perform rating on this stock but restated the target price of $44.
Ionis Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $23.95 and $52.34. Currently, Wall Street analysts expect the stock to reach $51.68 within the next 12 months. Ionis Pharmaceuticals Inc [NASDAQ: IONS] shares were valued at $43.59 at the most recent close of the market. An investor can expect a potential return of 18.56% based on the average IONS price forecast.
Analyzing the IONS fundamentals
Trailing Twelve Months sales for Ionis Pharmaceuticals Inc [NASDAQ:IONS] were 717.68M which represents 10.14% growth. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -0.66%, Pretax Profit Margin comes in at -0.65%, and Net Profit Margin reading is -0.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -0.92 and Total Capital is -0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.96.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 41.06 points at the first support level, and at 38.54 for the second support level. However, for the 1st resistance point, the stock is sitting at 44.91, and for the 2nd resistance point, it is at 46.24.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Ionis Pharmaceuticals Inc [NASDAQ:IONS] is 9.66. In addition, the Quick Ratio stands at 9.62 and the Cash Ratio stands at 1.06. Considering the valuation of this stock, the price to sales ratio is 9.67, the price to book ratio is 14.57.
Transactions by insiders
Recent insider trading involved Hayden Michael R, Director, that happened on May 01 ’25 when 15000.0 shares were purchased. EVP, Corp and Development Ops, Birchler Brian completed a deal on Apr 16 ’25 to sell 680.0 shares. Meanwhile, EVP, Chf GL Pdt Str Ofcr Jenne Kyle sold 3016.0 shares on Apr 16 ’25.
